US 12,135,301 B2
Point of care sepsis assay device and method
Phill Ainger, Liverpool (GB); Colin Downey, Liverpool (GB); and David George, Liverpool (GB)
Assigned to FREQUASENSE LIMITED, Liverpool (GB)
Appl. No. 17/913,029
Filed by FREQUASENSE LIMITED, Liverpool (GB)
PCT Filed Mar. 22, 2021, PCT No. PCT/GB2021/050698
§ 371(c)(1), (2) Date Sep. 20, 2022,
PCT Pub. No. WO2021/186198, PCT Pub. Date Sep. 23, 2021.
Claims priority of application No. 2004047 (GB), filed on Mar. 20, 2020.
Prior Publication US 2023/0146070 A1, May 11, 2023
Int. Cl. G01R 27/28 (2006.01); B01L 3/00 (2006.01); G01N 27/02 (2006.01); G01N 33/487 (2006.01); G01N 33/49 (2006.01)
CPC G01N 27/02 (2013.01) [B01L 3/502715 (2013.01); G01N 33/48707 (2013.01); G01N 33/49 (2013.01); B01L 2300/0645 (2013.01); B01L 2300/16 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An assay device configured to detect sepsis by measuring an electrical signal in a form of an inductive reactance of a sample of whole blood, plasma or serum, the device comprises a first electrode and a second electrode separated by a gap, wherein the gap is in fluid communication with an inlet configured to receive the sample and the first and second electrodes are configured to measure any very low density lipoprotein (VLDL) in the sample in the gap resonating at a frequency of 70-90 kHz when an alternating electric field is applied across the first and second electrodes.